24 dangerous pathogen groups are posing serious health risks, UK experts warn
Pathogens that cause the bird flu, COVID-19, and a bat-borne virus that causes brain swelling pose a risk to public health and could lead to the next pandemic, biosecurity experts in the United Kingdom have warned.
The UK Health Security Agency (UKHSA) identified 24 pathogen families as a health risk for one of several reasons: either they are highly contagious or cause serious disease, they do not have enough vaccines or treatments to combat them, or they could be exacerbated by climate change or antibiotic-resistant superbugs.
They include the pathogen groups behind illnesses like mpox, coronavirus, norovirus (or the winter vomiting bug), the flu, gonorrhoea, Ebola, Zika, Lassa fever, and Nipah virus, which is mainly spread by fruit bats and can cause brain swelling.
Related
How EU countries compare on readiness for the next health crisis
Eight of these pathogen families are at high or medium risk of causing a pandemic, the agency said. While there are vaccines and treatments available for some of them, many are still in clinical trials.
UKHSA officials called for more research and investment to keep the pathogens from spiralling into a bigger problem.
"We hope this will help to speed up vaccine and diagnostics development where it is most needed, to ensure we are fully prepared in our fight against potentially deadly pathogens," Dr Isabel Oliver, the UKHSA's chief scientific officer, said in a statement.
Related
EU's medicine stockpiling strategy challenged by national security concerns
Pathogen list 'a double edge sword'
Independent experts said the list could help streamline the UK's efforts to prepare for looming infectious disease threats.
It follows an update from the World Health Organization (WHO) last year that
named 33 "priority pathogens"
as pandemic-level risks.
However, Jose Vazquez-Boland, chair of infectious diseases at the University of Edinburgh, warned that the priority list could be a 'double-edged sword,' raising attention to high-risk pathogens but potentially undercutting research on those that did not make the cut.
Related
How well are countries in Europe dealing with health issues? New report shows progress is stagnating
Meanwhile, Emma Thomson, who directs the MRC-University of Glasgow Centre for Virus Research, urged the UKHSA to regularly update the priority list when new risks appear.
"It is essential that this list remains dynamic and responsive to emerging threats," Thomson said in a statement.
"History has shown that pandemic risks can arise from unexpected sources".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
LeMonde
15 hours ago
- LeMonde
US to partially pull funding for mRNA vaccines
The US administration waged a battle against messenger RNA (mRNA), despite promising research being conducted for various diseases. This technology was thrust into the spotlight during the Covid-19 pandemic, when it enabled the rapid rollout of effective vaccines. Gone are the days when Donald Trump, in December 2020 – at the end of his first term as US president – praised the effectiveness and swift development of this technology, calling it a "modern-day miracle." On Tuesday, August 5, US Health and Human Services Secretary Robert F. Kennedy Jr. launched a full-scale attack against it. Known for his vaccine skepticism, he announced the end of funding for projects related to the research and development of messenger RNA vaccines backed by the Biomedical Advanced Research and Development Authority (BARDA), the US government agency for public health emergency and pandemic preparedness. "We reviewed the science, listened to the experts, and acted," RFK Jr. said in a statement, asserting that the "data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu." In a video posted on the social network X, he went further, claiming that "mRNA technology poses more risks than benefits for these respiratory viruses."
Euronews
2 days ago
- Euronews
EU agencies seek to combat viral hepatitis in European prisons
EU agencies for disease prevention and drugs have together launched a toolkit to support efforts to eliminate viral hepatitis in Europe's prisons. The initiative by the European Centre for Disease Prevention and Control and the European Drugs Agency, supports the World Health Organisation's target to eliminate viral hepatitis as a public health threat by 2030. Published ahead of Prisoners' Justice Day (10 August), the guide aims to support hepatitis B and C prevention and care in prisons across Europe. It is primarily intended for professionals working in prison healthcare services and provides information on how to set up interventions to prevent and control viral hepatitis in these settings. The number of prisoners in the EU was around 499,000 in 2023, equivalent to 111 prisoners per 100,000 inhabitants, according to the European Commission, representing a 3.2% increase compared with 2022. In the EU, hepatitis B and C prevalence is highest among certain populations, including migrants, people who inject drugs, men who have sex with men, sex workers, and people in prison. This makes prisons a high-risk environment for hepatitis B and C transmission, as prison populations and people who inject drugs often overlap, according to the agencies. 'Incarceration and drug use are therefore intertwined and lead to increased risks of infection with communicable diseases,' the toolkit notes. The scarcity of access to clean injecting equipment in most prison settings further increases the risk, not only for drug use but also for tattoos and body piercings. Hepatitis B and hepatitis C are major causes of cirrhosis, liver cancer, liver transplantation, and liver related deaths. The WHO estimates that 10.6 million people in Europe are living with chronic hepatitis B, and 8.6 million with chronic hepatitis C, the majority of whom remain undiagnosed. Both agencies highlight the unique challenges of addressing this issue in the prison context — including insufficient resources, lack of training, and underdeveloped public health surveillance and monitoring systems — all of which can hinder the implementation of recommendations. They also stress the need to tackle these infections not only to improve individual health outcomes for prisoners but also to reduce transmission within prisons and in the wider community upon release.
Euronews
2 days ago
- Euronews
What we know about the West Nile virus spreading in Europe
Ten people have died of West Nile virus in Italy this year, with cases of the mosquito-borne illness also reported in other parts of Europe. As summer heats up, health authorities have warned Europeans to take steps to prevent themselves from being infected with the West Nile virus and other mosquito-borne illnesses, including chikungunya, dengue, and Zika. But what exactly do we know about the West Nile virus? Where does the virus come from? Spread through the bite of infected mosquitoes, the West Nile virus infects both humans and birds. But in very rare cases, it can also be transmitted through blood transfusions, organ transplants, and breast milk. Its name dates back to 1937, when it first appeared in the West Nile region of Uganda. It was introduced to the United States in 1999, and has since become widely established across the globe, according to the World Health Organization (WHO). Today, it is commonly found in Africa, Europe, the Middle East, North America, and west Asia. West Nile virus often spreads from mid summer to early autumn in regions with warmer weather. Research has shown that climate change is accelerating the spread of mosquito-borne viruses in Europe. In addition to Italy, infections have been reported in Bulgaria, France, Greece, and Romania this year, according to the European Centre for Disease Prevention and Control (ECDC). The virus was also detected in mosquitoes in the United Kingdom for the first time earlier this year. What are the symptoms of West Nile virus? Most people who are infected with West Nile virus will have no symptoms. But about one in five people will develop West Nile fiver, which causes body aches, headaches, vomiting, fatigue, rashes, and swollen lymph glands. Around one in 150 infected people develop a more serious form of the disease that can cause neurological complications, coma, tremours, convulsions, muscle weakness, and paralysis. Serious illness can occur in people of any age, however people over the age of 50 and some immunocompromised persons (for example, transplant patients) are at the highest risk for getting severely ill when infected with WNV. People with compromised immune systems and those over the age of 50 are at higher risk of these complications. In rare cases, West Nile virus can cause fatal neurological disease. What is recovery like? There is no vaccine or specific treatment for people with Nest Nile virus. Rest, fluids, and pain medications can help alleviate some symptoms. Patients with a neuro-invasive illness are usually hospitalised and given intravenous fluids and respiratory support while they recover, the WHO said. Once infected, people are believed to be protected against the virus for life. Beyond treatment, public health authorities are focused on preventing people from infection in the first place. These efforts rely heavily on local mosquito control programmes and personal protection. Authorities recommend that people use insect spray and wear long-sleeved shirts and trousers to keep themselves from being bitten by mosquitoes.
